Protheragen

Next-Generation PARP1-Selective Inhibitors with Improved Safety and CNS Penetration

Available for Licensing and Co-development

COMPANY PROFILE

P* Inc. is a U.S.-based company focused on advancing differentiated therapeutic assets addressing significant unmet medical needs. Led by an experienced, science-driven leadership team, the company leverages deep expertise and a global network of industry relationships to efficiently progress programs toward clinical and commercial partnering.

SEEKING OPPORTUNITIES

License-Out

Exclusive global development and commercialization rights.

Co-Development

Joint development with shared cost, risk, and value.

CONTACT DETAILS

Contact us for further discussion and access to the full BD deck.

www.protheragen.com

inquiry@protheragen.com

101-4 Colin Dr, Holbrook, NY 11741, USA

The Underserved PARP Inhibitor Market: Toxicity and CNS Challenge

The PARP inhibitor class is clinically validated but limited by two major challenges observed with first-generation agents (e.g., Olaparib).

- **Systemic Toxicity:** Non-selective inhibition of PARP2 contributes to dose-limiting hematologic toxicity, restricting combination regimens.
- **Central Nervous System (CNS) Barrier:** Limited Blood–Brain Barrier (BBB) penetration reduces therapeutic effect in brain metastases and gliomas, which remain significant unmet needs for a substantial proportion of cancer patients.

Differentiated Solution: PARP1 Selectivity and BBB Penetration

P* Inc.' program is designed to address these limitations through highly selective PARP1 inhibition and assets optimized for BBB penetration.

Target: PARP1

Drug Modality: Small molecule

Mechanism: Selective inhibition of PARP1 while sparing PARP2 aiming to reduce hematologic toxicity and enable a broader therapeutic window.

Dual-Asset Strategy: Two optimized candidates under a single IP umbrella, enabling coverage of systemic and CNS-focused oncology markets.

Protheragen

Assets and Competitive Edge

Assets	Phase	Strategic Focus	Result Summary	Competitive Edge
MC-01-4-0	Preclinical	Systemic therapy optimization	- Demonstrated biochemical PARP1 inhibition and *in vitro* efficacy - *In vivo* efficacy in oncology mode - Mouse and dog PK	**Differentiated safety profile** via PARP2 sparing. **Comparable efficacy** vs. AZD5305 with manageable body-weight maintenance.
MC-01-6-0	Preclinical	CNS-penetrant, PARP1-selective inhibitor	- Demonstrated biochemical PARP1 inhibition and *in vitro* efficacy - *In vivo* efficacy - Mouse PK	**Differentiated safety profile** via PARP2 sparing. Optimized physicochemical properties supporting **BBB penetration**.

Intellectual property

The core chemical scaffold is protected by a global PCT patent application (PCT/US2025/034796, filed June 23, 2025). The claims cover novel compounds, pharmaceutical compositions, and broad therapeutic applications across multiple disease areas.

About Us

Headquartered in New York, Protheragen is a US-based company specializing in the global pharmaceutical and biomedical sectors. Our core services aim to precisely connect innovative pharmaceutical assets with potential partners worldwide, efficiently facilitating diverse strategic collaborations including, but not limited to: Licensing-out, Financing, Co-development, and Mergers & Acquisitions.